Lunit’s AI solution for x-ray analysis gains CE certification

Lunit, a medical software company based out of South Korea, has gained CE certification for its newest chest x-ray analysis solution, Lunit INSIGHT CXR.

The solution uses AI technology to identify a total of 10 chest abnormalities—including pneumothorax, fibrosis and more—and crafts reports for the radiologist that summarize each finding. Lunit INSIGHT CXR can also be used to screen patients for tuberculosis.

“We are delighted to announce that one of our most mature products, Lunit INSIGHT CXR, has won CE marking,” Brandon Suh, MD, Lunit CEO, said in a prepared statement. “We look forward to installations among hospitals across Europe, where an improvement in healthcare services in the region can greatly impact many people’s lives.”

“Lunit INSIGHT CXR has been evolving ever since its first introduction at RSNA 2017,” Sunggyun Park, PhD, head of chest radiology at Lunit, said in the same statement. “According to our reader study published in Radiology, our product can greatly improve reader performance by 20% at the highest. It can support radiologists to gain efficiency in the day to day workflow.”

The solution—which Lunit will be displaying at RSNA 2019 in Chicago—is already installed in Mexico, China, Thailand, Korea and UAE.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.